Last reviewed · How we verify

NCT07217392: LBBAP PMCF

Left Bundle Branch Area Pacing (LBBAP) PMCF Study

Recruiting now NA Last updated 16 October 2025
What this trial tests

NA trial testing LBBAP lead in Bradycardia in 200 participants. Currently enrolling.

Timeline
24 July 2025
Primary endpoint
30 April 2027
30 April 2027

Quick facts

Lead sponsorAbbott Medical Devices
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment200
Start date24 July 2025
Primary completion30 April 2027
Estimated completion30 April 2027
Sites2 locations across India

Drugs / interventions tested

Conditions studied

Sponsor

Abbott Medical Devices — full company profile →

Who can join

18 and older, any sex, with Bradycardia or Right Ventricular Pacing. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate the safety and effectiveness of LBBA pacing/sensing in patients implanted with the Tendril STS 2088TC or UltiPace LPA1231 lead through 6 months post-implant.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Bradycardia

Currently open trials in the same condition.

Other Abbott Medical Devices trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07217392.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing